Mainz Biomed (MYNZ) said Thursday it signed an exclusive license agreement with Liquid Biosciences to develop a blood-based test for detecting pancreatic cancer using mRNA biomarkers.
The company said the financial terms include a license fee and royalties on potential future revenue without disclosing specific details.
Under the agreement, Mainz Biomed will develop the test using Liquid Biosciences' biomarkers, with an option to acquire exclusive global rights, the company said.
The companies plan to refine the test and prepare for a potential submission to the US Food and Drug Administration, Mainz said.
MYNZ shares were 0.8% higher in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.